Compare FDMT & PDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDMT | PDT |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 581.9M |
| IPO Year | 2019 | 1994 |
| Metric | FDMT | PDT |
|---|---|---|
| Price | $10.21 | $11.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $28.09 | N/A |
| AVG Volume (30 Days) | ★ 855.5K | 136.0K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $6.96 | $11.49 |
| 52 Week High | $16.93 | $13.65 |
| Indicator | FDMT | PDT |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 32.10 |
| Support Level | $8.43 | $11.49 |
| Resistance Level | $10.61 | $13.02 |
| Average True Range (ATR) | 0.85 | 0.17 |
| MACD | -0.15 | -0.05 |
| Stochastic Oscillator | 1.07 | 1.34 |
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.